Albert J. Aboulafia1*
Nicole Liddy1Lauren Zeitlinger2Diana W. Molavi3
Sudarsan Murali1David Aboulafia4- 1Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
- 2Department of Orthopaedic Surgery, UPMC Children’s Specialty Services, Lancaster, PA, United States
- 3Department of Pathology, Sinai Hospital of Baltimore, Baltimore, MD, United States
- 4Department of Hematology/Oncology, Virginia Mason Medical Center, Seattle, WA, United States
Nodular fasciitis is a common benign tumor resulting from reactive proliferation of fibroblasts and myofibroblasts. It most often presents as a firm and solitary lump in the subcutaneous fat layer or fascia adjacent to muscles in the extremities. Because of its rapid growth and high cellularity, it may mimic soft-tissue sarcoma, but it is self-limiting, often resolving with fibrosis. The evolution of benign nodular fasciitis to malignant nodular fasciitis is distinctly uncommon, and only a handful of cases have been reported in the medical literature. Herein we describe the case of a woman with a 21-year history of multifocal nodular fasciitis superimposed on malignant nodular fasciitis. Her course has been characterized by rapid tumor growth and widespread dissemination. Over the course of 2l years she underwent multiple surgical procedures. Ultimately, molecular studies demonstrated a fusion of protein phosphatase 6 regulatory subunit 3 (PPP6R3)–ubiquitin specific peptidase 6 (USP6), suggesting an oncogenic mechanism despite classic histologic features of benign nodular fasciitis with aggressive behavior. She subsequently received systemic therapy, initially with temozolomide and later pazopanib, followed by sunitinib. With the later medication she has achieved a good response of now more than 18 months. This case illustrates the importance of molecular drivers of cancer in a benign soft-tissue tumor and the potential to offer targeted therapies to extend patient survival. This rare case highlights the potential malignant behavior of nodular fasciitis associated with PPP6R3-USP6 fusion.
1 Introduction
Nodular fasciitis is a benign, self-limiting myofibroblastic proliferation that typically presents in young adults as a rapidly growing mass, most commonly in the forearm or thigh (1–5). On imaging, it may mimic soft-tissue sarcoma, but characteristic histologic findings, including tissue-culture-like fibroblasts within a myxoid or collagenous stroma, help distinguish it from malignancy (1, 6–8). Although traditionally considered reactive, nodular fasciitis has demonstrated neoplastic potential with recent identification of ubiquitin specific peptidase 6 (USP6) gene rearrangements (9–11).
We report a case of deep thigh nodular fasciitis with distant metastases. Despite biopsies from multiple metastatic sites, histologic findings remained typical. Molecular analysis of the tumor yielded a unique protein phosphatase 6 regulatory subunit 3 (PPP6R3)-USP6 gene fusion rearrangement, a novel discovery thought to account for the unusual malignant behavior. USP6 is essential in signaling pathways, functioning as a deubiquitinase leading to cellular proliferation and activation of transcription factors (12). USP6 is a deubiquitinating enzyme involved in multiple signaling pathways as a potent oncogene when overexpressed, typically through chromosomal translocations. It has been shown to drive cancer progression in mesenchymal tumors and is associated with sarcomas. It acts to remove ubiquitin chains, leading to several signaling pathways that drive cellular proliferation and transformation. Identified signaling pathways include Wnt/β-catenin, JAK/STAT, and NF-kB.
2 Case description
A 40-year-old woman with no relevant medical history presented to the musculoskeletal oncology service in 2003 with a 3-month history of right buttock discomfort after a fall. Initially treated for muscle strain, she later noticed a right groin mass with quadriceps atrophy. Examination revealed an ill-defined 10×8–cm firm, mobile, deep-seated nontender mass in the right anterolateral thigh. MRI showed an ill-defined, heterogeneous mass involving the proximal quadriceps muscles (Figures 1A, B). Core needle biopsy yielded a diagnosis of nodular fasciitis (Figures 2A, B).
Figure 1. (A) Coronal T2-weighted magnetic resonance image of bilateral femurs taken in June 2004, with arrow showing ill-defined mass with intramuscular signal abnormalities involving the right proximal rectus femoris, vastus intermedius, and vastus lateralis muscles. (B) Axial T2-weighted magnetic resonance images of bilateral femurs taken in June 2005 with arrow showing progression of disease and new involvement of the sartorius, quadriceps, vastus lateralis, and iliopsoas with the tumor also now circumferentially encasing the femoral nerve.
Figure 2. Hematoxylin and eosin staining confirming a myofibroblastic proliferation of cells in a storiform pattern on low power (A), with edematous areas with extravasated red blood cells and bland, euchromatic cells with tapering processes, giving a “tissue culture” appearance on high power (B), typical of nodular fasciitis. The histopathological appearance of this lesion remains unchanged over the years, including specimens obtained from the thigh (C) and shoulder (D) 13 years after diagnosis.
Her condition remained stable until late 2004, when she developed progressive thigh pain and sensory loss. Repeat core needle biopsy reaffirmed nodular fasciitis, and she underwent intralesional resection of the tumor involving the right thigh and neurolysis of the femoral nerve, with subsequent improvement in extremity dysesthesias. Wide excision was unfeasible because of the mass’s ill-defined border and vascular encasement. Because of the persistent behavior of the tumor and lack of spontaneous regression, pathology results were reviewed by 4 soft-tissue pathologists: 3 diagnosed nodular fasciitis, and 1 suggested a “low-grade malignant process.”
Pelvic and thigh MRI 4 months later showed extensive soft-tissue changes within the anterior and medial compartments of the thigh (Table 1; Figures 1C, D), with the mass noted circumferentially around the femoral nerve. Another biopsy provided no new information. Given the lack of expected regression, an aggressive compartmental resection of the lesion and associated neurovascular structures was discussed. In the absence of a clear diagnosis of malignancy, the patient chose to continue surveillance. Inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate were not collected, nor were cytokine measurements such as interleukin-6 and tumor necrosis factor-α.
Table 1. Chronological summary of imaging findings for a woman with malignant nodular fasciitis.
Between 2005–2011, the tumor grew slowly, and the patient was diagnosed with bilateral pulmonary emboli from deep vein thrombosis of the right femoral and popliteal veins due to tumor compression. MRI in 2011 showed new lesions in the medial gastrocnemius and plantaris muscles (Figure 3). Between 2011–2012, methylprednisolone injections provided temporary relief from calf pain and swelling. In 2013, MRI confirmed enlargement of the anterior right thigh mass (to 8.2×2.7×3.4 cm) and new masses in the left thigh (11.3×3.4×5.4 cm), medial right thigh (12×4.8×5.1 cm), left calf (6.1×2.7×2.9 cm), left gluteus (9.1×1.2 cm), and right hemipelvis (2.5×1.6 cm). Signal characteristics and several biopsies of each lesion did not vary over time, and the masses demonstrated slow, continued growth (Table 1).
Figure 3. Coronal (A) and axial (B) T2-weighted magnetic resonance images of lower legs taken in December 2011. Note the right lower leg image showing a medial gastrocnemius mass measuring 1.6×2.1 cm (left arrow) and a second mass in the plantaris muscle measuring 1.9×3.1×2.3×2.6 cm (right arrow).
In 2014, the right thigh masses began to enlarge rapidly, and fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) showed hypermetabolic activity in the lower-extremity lesions and new disease within the left antecubital fossa and right transverse abdominus musculature, with standardized uptake values ranging from 5.1–12.9 (Figure 4). She received a total of 50 Gy of hyper-fractionated external beam radiotherapy to areas of bulky and symptomatic disease, but this provided no relief or measurable response clinically or radiographically.
Figure 4. Positron emission tomography/computed tomography images of upper (A) and lower (B) body taken in late 2014, showing increased tracer uptake in the proximal right radius with maximum standardized uptake value (SUV) of 5.5; linear increased uptake in the right supinator (SUV of 3.1); left antecubital fossa (SUV of 12.0); increased tracer activity in the right lower abdomen/pelvis (SUV of 17.1); right thigh adductors (SUV of 14.1); right popliteal region (SUV of 14.4); left hip with increased uptake (SUV of 8.6); left adductors (SUV of 15.3); and left quadriceps (SUV of 13).
Again, aggressive sampling of the most symptomatic lesions within the right thigh, calf, and antecubital fossa showed no substantial histological change (Figures 2C, D), and a diagnosis of malignancy could not be rendered. However, the PPP6R3-USP6 gene fusion was identified in 2016 by fluorescence in situ hybridization (13). On the basis of this novel gene rearrangement, she was diagnosed with malignant nodular fasciitis and received oral temozolomide (140 mg daily, 6 weeks on and 3 weeks off). This regimen was later switched to 2 weeks on therapy and 1 week off. Chemotherapy was well tolerated but provided no appreciable benefit and was discontinued.
FDG-PET/CT in late 2018 showed persistent, progressive multifocal disease with new lesions throughout bilateral upper and lower extremities and no visceral or solid-organ disease. Subsequent repeat resections yielded no pathologic change, with continued local recurrence. In mid-2021, she began systemic treatment with pazopanib 800 mg daily, which produced considerable shrinkage of the lesions. At 2 months, she had lost more than 4 kg due to improved lymphedema and was satisfied with her progress. Her disease remained stable for the next 2 years, but in late 2023, she developed a painful right posterior shoulder mass and noted progression of the left anterolateral thigh mass. PET/CT showed avid uptake in both areas, and MRI of the shoulder revealed a large, infiltrative mass involving the rotator cuff musculature and joint capsule. In response, she was transitioned from pazopanib to sunitinib, which provided temporary pain relief, and PET/CT showed decreased FDG avidity. After approximately a year, however, her symptoms began to worsen.
In 2024, she underwent resection of the left thigh and right shoulder lesions for pain control, with 70 Gy of preoperative radiation to the thigh. Since this resection, she remains on sunitinib. Pathology analysis from both sites continues to show similar malignant nodular fasciitis, and genetic tumor markers show PPP6R3-USP6 fusion and an ERBB2 (erb-b2 receptor tyrosine kinase 2) mutation (p.R188C). She is doing well, with less pain, and continued ability to walk. She continues to experience lower-extremity lymphedema and symptoms related to mass effect on adjacent neurologic structures.
3 Discussion
Nodular fasciitis is historically regarded as a benign, self-limiting condition (2, 5). This report builds upon the molecular findings of Guo et al. (9), providing long-term clinical follow-up, treatment outcomes, and additional genomic alterations. Guo et al. reported on the first case of USP6-driven oncogenesis in a case of histologically benign–appearing nodular fasciitis with malignant behavior, and the coauthors are credited with coining the term “malignant nodular fasciitis.”
Despite 21 years of histologic confirmation of benign nodular fasciitis, our patient showed progressive, multifocal disease. This atypical presentation may be explained by a novel oncogenic mechanism (PPP6R3-USP6 fusion) that has been reported in other neoplasms and, more recently, in rare cases of histologically benign nodular fasciitis with clinically aggressive behavior (10, 11). Saoud et al. (10) reported a single-institution study of 7 patients with nodular fasciitis with novel USP6 gene fusions that presented with “aggressive clinical behavior.” In 1 case over a 9-year period, the mass enlarged to the point that it created erosive changes in the adjacent femur. In another case, the patient developed pulmonary metastases and died of disease. Teramura et al. (11) reported on a patient with PPP6R3-USP6 gene amplification and a mass that grew rapidly and was treated with wide resection (Table 2). Aside from the patient who developed pulmonary metastases, we are aware of no other cases demonstrating metastatic disease and none demonstrating soft-tissue metastases in the absence of pulmonary metastases. Thus, we reserve the term “malignant nodular fasciitis” for metastatic disease in otherwise histologically benign–appearing nodular fasciitis and not simply cases of “aggressive” local behavior.
Table 2. Published cases with similar presentation to the patient in the current report.
“Malignant nodular fasciitis” is a term reserved for conditions when histologic testing shows no evidence of malignancy yet the tumor behaves clinically in a malignant fashion. In this case, the patient developed extensive soft-tissue metastases (hence the term “malignant”) while histologic findings remained consistent with benign nodular fasciitis. Low-grade malignant nodular fasciitis represents a true malignant tumor. The differences lie in their disparate clinical behavior, biological features, and molecular profiles, which are essential and provide pathologists with a nuanced identification process when there is morphological overlap. Typically, nodular fasciitis grows rapidly, measures less than 5 cm, is superficial to fascia involving the upper extremities, head, neck or trunk, and (most importantly) resolves spontaneously or is cured with local excision. In contrast, low-grade malignant nodular fasciitis grows slowly, is typically larger than 5 cm, is deep to fascia, does not spontaneously resolve, and often requires wider margins to achieve local control because of its infiltrative pattern of growth.
Next-generation sequences later identified a somatic ERBB2 p.R188C mutation in tumor tissue. Although this variant has been reported in other malignancies, including breast and lung cancer, it has not been reported in nodular fasciitis (14). This is the first reported case of nodular fasciitis with both alterations. Our patient never achieved signs of spontaneous regression nor durable response to surgery, radiotherapy, or chemotherapy. Though inexorably progressive in its clinical course, this entity also differs from the behavior of conventional soft-tissue sarcomas, showing slow local growth and extremity spread without visceral or lymphatic involvement (15).
We believe this case is the only known patient to receive chemotherapy for nodular fasciitis. Chemotherapy was initiated after identifying a PPP6R3-USP6 gene fusion in her tumors. This genetic aberration results in transcriptional upregulation of USP6, a known oncogene in Ewing sarcoma and aneurysmal bone cysts (9, 16, 17). Molecular profiling (Caris Life Sciences, Irving, TX) was negative for the biomarkers O[6]-methylguanine-DNA methyltransferase by immunohistochemistry, suggesting a potential therapeutic effect with temozolomide. Temozolomide is an alkylating agent that has antitumor activity in gliomas and other solid tumors (18, 19). In glioma cells, it has autophagic properties that impair cellular adhesion, reducing cellular viability (20). Our patient was treated “off-label” with temozolomide because of its reliable bioavailability, relatively nontoxic effects, and broad potential for several refractory tumor types (18, 20, 21). Treatment failed to reduce tumor burden. Our patient was also trialed on tyrosine kinase inhibitor, pazopanib, with remarkable results. She was transitioned to sunitinib because of intolerable diarrhea. Sunitinib has greater tyrosine kinase activity and continues to provide excellent results while we wait for a potential clinical trial of cyclin-dependent kinase 9 inhibitor.
A previous report on nodular fasciitis describes recurrence rates of less than 2% (22). While bilateral extremity involvement has been observed, few cases of multifocal nodular fasciitis and even fewer of malignant nodular fasciitis have been reported. We present this case to highlight the malignant clinical behavior with retained benign histology and treatment-refractory nature of this disease. The major strength of this report is the 21-year longitudinal follow-up with histologic, radiologic, and molecular correlation, including response to multiple systemic therapies. However, the findings may have limited generalizability because of the uniqueness of the genetic alterations in this patient. Continued follow-up is warranted to determine whether targeted therapy against USP6 amplification provides ongoing benefit to this patient and others with this genomic signature.
4 Conclusion
This case illustrates a rare and challenging presentation of histologically benign but clinically malignant nodular fasciitis, associated with a PPP6R3-USP6 fusion and ERBB2 mutation. Despite the lack of histologic transformation over time, the tumor exhibited progressive multifocal growth, resistance to conventional treatment, and required systemic therapy. The patient’s prolonged clinical course emphasizes the need for molecular profiling in atypical soft-tissue tumors and supports consideration of targeted therapies in future management. Furthermore, this case highlights the need for development of a molecularly guided classification system for USP6-driven neoplasms and supports incorporating genomic testing into the diagnostic algorithm of recurrent, multifocal/metastatic “histologically benign” myofibroblastic lesions that have a malignant clinical course.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for the studies involving humans because this is a case report, for which the patient consented to publication. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
AA: Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review & editing. NL: Visualization, Writing – original draft, Writing – review & editing. LZ: Conceptualization, Investigation, Writing – original draft. DM: Conceptualization, Investigation, Writing – original draft. SM: Investigation, Writing – original draft. DA: Writing – original draft, Investigation, Conceptualization.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
For editorial assistance, we thank Rachel Walden, MS, in the Editorial Services group of The Johns Hopkins Department of Orthopaedic Surgery.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
2. Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Investig J Tech Methods Pathol. (2011) 91:1427–33. doi: 10.1038/labinvest.2011.118
3. Shimizu S, Hashimoto H, and Enjoji M. Nodular fasciitis: an analysis of 250 patients. Pathol (Phila). (1984) 16:161–6. doi: 10.3109/00313028409059097
4. Kumaran A and Puthenparambath S. Fine-needle aspiration diagnosis of nodular fasciitis: A case report. J Cytol Indian Acad Cytol. (2016) 33:172–4. doi: 10.4103/0970-9371.188064
5. Tomita S, Thompson K, Carver T, and Vazquez WD. Nodular fasciitis: a sarcomatous impersonator. J Pediatr Surg. (2009) 44:e17–19. doi: 10.1016/j.jpedsurg.2009.01.047
6. Dinauer PA, Brixey CJ, Moncur JT, Fanburg-Smith JC, and Murphey MD. Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults. Radiogr Rev Publ Radiol Soc N Am Inc. (2007) 27:173–87. doi: 10.1148/rg.271065065
7. Leung LYJ, Shu SJ, Chan ACL, Chan MK, and Chan CHS. Nodular fasciitis: MRI appearance and literature review. Skeletal Radiol. (2002) 31:9–13. doi: 10.1007/s002560100411
8. Vanhoenacker FM, Rekik MM, and Salgado R. Pseudotumoral lesions. In: Vanhoenacker FM, Parizel PM, and Gielen JL, editors. Imaging of Soft Tissue Tumors. Springer International Publishing, Cham (2017). p. 523–75. doi: 10.1007/978-3-319-46679-8_21
9. Guo R, Wang X, Chou MM, Asmann Y, Wenger DE, Al-Ibraheemi A, et al. PPP6R3-USP6 amplification: Novel oncogenic mechanism in Malignant nodular fasciitis. Genes Chromosomes Cancer. (2016) 55:640–9. doi: 10.1002/gcc.22366
10. Saoud C, Agaimy A, Stoehr R, Michal M, Wang SK-W, Mandavilli S, et al. Nodular fasciitis: a case series unveiling novel and rare gene fusions, including two cases with aggressive clinical behavior. Virchows Arch Int J Pathol. (2025). doi: 10.1007/s00428-025-04040-6
11. Teramura Y, Yamazaki Y, Tanaka M, Sugiura Y, Takazawa Y, Takeuchi K, et al. Case of mesenchymal tumor with the PPP6R3-USP6 fusion, possible nodular fasciitis with Malignant transformation. Pathol Int. (2019) 69:706–9. doi: 10.1111/pin.12851
12. Syed S, Painda MYK, Ghafoor D, Gu D, and Wang F. Physiological roles and therapeutic implications of USP6. Cell Death Discov. (2025) 11:231. doi: 10.1038/s41420-025-02466-0
13. Patel NR, Chrisinger JSA, Demicco EG, Sarabia SF, Reuther J, Kumar E, et al. USP6 activation in nodular fasciitis by promoter-swapping gene fusions. Mod Pathol Off J U S Can Acad Pathol Inc. (2017) 30:1577–88. doi: 10.1038/modpathol.2017.78
14. Greulich H, Kaplan B, Mertins P, Chen T-H, Tanaka KE, Yun C-H, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. (2012) 109:14476–81. doi: 10.1073/pnas.1203201109
15. Vezeridis MP, Moore R, and Karakousis CP. Metastatic patterns in soft-tissue sarcomas. Arch Surg Chic Ill 1960. (1983) 118:915–8. doi: 10.1001/archsurg.1983.01390080023007
16. Oliveira AM and Chou MM. USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol. (2014) 45:1–11. doi: 10.1016/j.humpath.2013.03.005
17. Bekers EM, Eijkelenboom A, Grünberg K, Roverts RC, de Rooy JWJ, van der Geest ICM, et al. Myositis ossificans - Another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst. Ann Diagn Pathol. (2018) 34:56–9. doi: 10.1016/j.anndiagpath.2018.01.006
18. Friedman HS, Kerby T, and Calvert H. Temozolomide and treatment of Malignant glioma. Clin Cancer Res Off J Am Assoc Cancer Res. (2000) 6:2585–97.
19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005) 352:987–96. doi: 10.1056/NEJMoa043330
20. Shen W, Hu J-A, and Zheng J-S. Mechanism of temozolomide-induced antitumour effects on glioma cells. J Int Med Res. (2014) 42:164–72. doi: 10.1177/0300060513501753
21. Villano JL, Seery TE, and Bressler LR. Temozolomide in Malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. (2009) 64:647–55. doi: 10.1007/s00280-009-1050-5
22. Fletcher C, Unni K, and Mertens F eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. 3rd ed. Lyon, France: International Agency for Research on Cancer (2002). Available online at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-Soft-Tissue-And-Bone-2002. (Accessed January 2025).
Keywords: multifocal soft-tissue sarcoma, nodular fasciitis, soft-tissue metastasis, soft-tissue sarcoma, USP6
Citation: Aboulafia AJ, Liddy N, Zeitlinger L, Molavi DW, Murali S and Aboulafia D (2026) Malignant nodular fasciitis, a rare manifestation of a benign disease: case report. Front. Oncol. 16:1685315. doi: 10.3389/fonc.2026.1685315
Received: 13 August 2025; Accepted: 12 January 2026; Revised: 07 January 2026;
Published: 21 January 2026.
Edited by:
Catrin Sian Rutland, University of Nottingham, United KingdomReviewed by:
Francesk Mulita, General Hospital of Eastern Achaia- Unit of Aigio, GreeceUgo Maria Pierucci, Ospedale dei Bambini Vittore Buzzi, Italy
Copyright © 2026 Aboulafia, Liddy, Zeitlinger, Molavi, Murali and Aboulafia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Albert J. Aboulafia, YWFib3VsYTFAamh1LmVkdQ==